JAHA:冠脉手术后的桡动脉和尺动脉阻塞以及抗凝治疗的影响

2017-09-12 xiangting MedSci原创

RAO和UAO发生频率相似,当冠脉手术后进行血管超声早期评估时大约为7%-8%。

现有文献中关于冠脉手术中桡动脉阻塞(RAO)和尺动脉阻塞(UAO)的发生率,前臂动脉阻塞的易感因素,抗凝治疗的益处有很大的不同。这项研究试图确定RAO/UAO的发生率和抗凝强度的影响。

纳入112项评估RAO和/或UAO(N = 46 631)的Meta分析。总体而言,粗RAO和UAO率(5.2%; 95%置信区间[CI],4.4-6.0 vs.4.0%; 95%CI,2.8-5.8; P = 0.171)没有差异。早期阻塞率(住院期间或术后7天)高于晚期阻塞率。与仅临床评估相比,血管超声检查的阻塞检出率较高。与高剂量肝素相比,低剂量肝素与RAO率更高相关(7.2%; 95%CI,5.5-9.4%vs 4.3%; 95%CI,3.5-5.3; Q = 8.81; P= 0.003)。低剂量肝素组的早期阻塞率为8.0%(95%CI,6.1-10.6)。与冠状动脉介入治疗相比,诊断血管造影后的RAO率较高,推测归因于冠脉介入的抗凝强度较高。止血技术(专利与非专利止血),地理位置(美国与非美国队列)和护套尺寸不影响血管通畅。

RAO和UAO发生频率相似,当冠脉手术后进行血管超声早期评估时大约为7%-8%。更强的抗凝治疗具有保护性。晚期再通发生在少数患者中。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696762, encodeId=6fac1696e624b, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Mon Jun 04 17:16:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267538, encodeId=708b126e538a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441098, encodeId=2ea61441098c5, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243215, encodeId=4f9c243215ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/23/87f97558da042e169592d0a8d56645fd.jpg, createdBy=d6a41700255, createdName=1de7cbd0m98(暂无匿称), createdTime=Tue Sep 12 13:11:08 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243199, encodeId=f0fa24319953, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:33:53 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243196, encodeId=d0a824319637, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Sep 12 12:10:39 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
    2018-06-04 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696762, encodeId=6fac1696e624b, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Mon Jun 04 17:16:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267538, encodeId=708b126e538a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441098, encodeId=2ea61441098c5, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243215, encodeId=4f9c243215ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/23/87f97558da042e169592d0a8d56645fd.jpg, createdBy=d6a41700255, createdName=1de7cbd0m98(暂无匿称), createdTime=Tue Sep 12 13:11:08 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243199, encodeId=f0fa24319953, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:33:53 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243196, encodeId=d0a824319637, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Sep 12 12:10:39 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
    2017-09-14 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696762, encodeId=6fac1696e624b, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Mon Jun 04 17:16:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267538, encodeId=708b126e538a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441098, encodeId=2ea61441098c5, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243215, encodeId=4f9c243215ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/23/87f97558da042e169592d0a8d56645fd.jpg, createdBy=d6a41700255, createdName=1de7cbd0m98(暂无匿称), createdTime=Tue Sep 12 13:11:08 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243199, encodeId=f0fa24319953, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:33:53 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243196, encodeId=d0a824319637, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Sep 12 12:10:39 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696762, encodeId=6fac1696e624b, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Mon Jun 04 17:16:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267538, encodeId=708b126e538a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441098, encodeId=2ea61441098c5, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243215, encodeId=4f9c243215ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/23/87f97558da042e169592d0a8d56645fd.jpg, createdBy=d6a41700255, createdName=1de7cbd0m98(暂无匿称), createdTime=Tue Sep 12 13:11:08 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243199, encodeId=f0fa24319953, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:33:53 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243196, encodeId=d0a824319637, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Sep 12 12:10:39 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
    2017-09-12 1de7cbd0m98(暂无匿称)

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1696762, encodeId=6fac1696e624b, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Mon Jun 04 17:16:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267538, encodeId=708b126e538a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441098, encodeId=2ea61441098c5, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243215, encodeId=4f9c243215ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/23/87f97558da042e169592d0a8d56645fd.jpg, createdBy=d6a41700255, createdName=1de7cbd0m98(暂无匿称), createdTime=Tue Sep 12 13:11:08 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243199, encodeId=f0fa24319953, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:33:53 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243196, encodeId=d0a824319637, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Sep 12 12:10:39 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
    2017-09-12 清风拂面

    谢谢分享.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1696762, encodeId=6fac1696e624b, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Mon Jun 04 17:16:00 CST 2018, time=2018-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267538, encodeId=708b126e538a9, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441098, encodeId=2ea61441098c5, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Thu Sep 14 02:16:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243215, encodeId=4f9c243215ac, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/23/87f97558da042e169592d0a8d56645fd.jpg, createdBy=d6a41700255, createdName=1de7cbd0m98(暂无匿称), createdTime=Tue Sep 12 13:11:08 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243199, encodeId=f0fa24319953, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:33:53 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243196, encodeId=d0a824319637, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Tue Sep 12 12:10:39 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
    2017-09-12 smartxiuxiu

    好!

    0

相关资讯

阜外医院李建军等在ATVB杂志发表研究,接受冠脉造影的患者中有3.5%为可能或明确家族性高胆固醇血症,但无一人LDL-C达标

近期中国医学科学院阜外医院李建军等在8000余例冠脉造影患者中进行的研究发现,有3.5%的患者具有明确(1%)和可能(2.5%)的家族性高胆固醇血症,但无一人低密度脂蛋白胆固醇(LDL-C)控制达标。 研究显示,在这8000余人中,女性患家族性高胆固醇血症为4.7%,远高于男性的2.9%。此外,不论男女,≤40岁以下者家族性高胆固醇血症更为多见,其中女性患病率为13.5%,男性患病率为9.3%(图

Heart:冠脉造影与心衰的预后有关?

对于较严重的心衰患者,往往会行冠脉造影术,然而,心衰患者冠状动脉造影术的决定因素和相关临床结果知之甚少。 本研究(BIOSTAT-CHF)纳入了2516名有明显临床症状的心衰患者,包括住院治疗的病人和院外治疗的患者。研究结果显示,有315名(12.5%)心衰患者在出现了明显临床症状后30天内接受了冠脉造影术。在接受了冠脉造影的患者中,大多数是住院病人,伴有较明显的急性冠脉综合征,肌钙蛋白I的

Radiology:等渗好还是低渗好?碘克沙醇和碘普罗胺在冠状动脉CT血管成像的显影效果。

离子型:离子型造影剂按结构分为单酸单体和单酸二聚体。单酸单体的代表药物有泛影葡胺(可用于各种血管造影及静脉肾孟造影。用于不同器官时,其浓度亦不同)、碘他拉葡胺等。离子型造影剂的副反应发生率高,肌体的耐受性差。非离子型碘造影剂较离子型毒副作用小,可用于各种血管造影及经血管的造影检查。非离子型造影剂副反应发生率低,肌体的耐受性好。本研究为了验证在以相同碘注射率的条件下注射相同或较低剂量的对比剂时通过C

JASN:冠状动脉造影患者血清尿调节素与死亡风险之间有啥关系?

将血清尿调节素浓度添加至心血管风险预测评分可以提高风险预测。因此,尿调节素可能是心血管和肾脏健康的一个有用的标记。

JACC:对症状稳定的冠脉疾病是采用功能测试还是冠脉造影?

对怀疑有冠脉疾病的稳定患者进行初步评估时,冠状动脉CTA与随后使用他汀类药物、阿司匹林和有创手术比例更高有相关性,治疗成本高于功能测试。

Ann Intern Med:冠脉造影是否可降低不稳定性心绞痛死亡率

非ST段抬高型急性冠脉综合征包括不稳定性心绞痛和非ST段抬高型心肌梗死。大多数对比常规与选择性侵入性冠状动脉造影随机对照试验的对照组和干预组具有较高的交叉率,并且没有包括不稳定性心绞痛的亚组分析。因此,关于在不稳定性心绞痛中使用血管造影术,没有明确的具体建议。